0305 GMT - The chances of the Biosecure Act, which targets Chinese biotech companies, being passed by the outgoing Biden administration are diminishing due to the lack of time, Citi analysts say in a research note. The Biosecure Act was not included in the U.S. fiscal 2025 National Defense Authorization Act released on December 7. Citi analysts view this development as "more positive" than expected. While this does not rule out the possibility of the legislation being passed next year, the market is likely to react positively to the news today, they note. WuXi AppTec's H shares rise 8.2% to HK$59.05 and WuXi Biologics climbs 9.2% to HK$18.94. (sherry.qin@wsj.com)
(END) Dow Jones Newswires
December 08, 2024 22:05 ET (03:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。